Description
Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials. Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa. Delafloxacin is currently in phase III evaluation for treatment of community-acquired pneumonia and was classified as a qualified infectious disease product by the U.S. FDA in its approval.
Uses
Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa.
Indications
Delafloxacin meglumine (Baxdelae Melinta) is a fluoroquinolone antibacterial agent with properties that are most similar to other members of this class, such as levofloxacin, moxifloxacin, and ciprofloxacin. It is supplied in formulations for oral and intravenous administration. It is indicated for the treatment of adults with ABSSSIs caused by susceptible isolates of the gram-positive bacteria Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, and Enterococcus faecalis, and the gram-negative bacteria Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa. It is the first fluoroquinolone to be demonstrated to be effective in the treatment of infections caused by MRSA, and its spectrum of antibacterial action, which also includes problem pathogens such as Pseudomonas aeruginosa, is broader than that of other antimicrobial agents that are indicated for the treatment of ABSSSIs[1].
Biological Activity
Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine is a broad spectrum fluoroquinolone antibiotic. Delafloxacin has a wide range of activity against drug-resistant Staphylococcus aureus, Streptococcus pneumoniae and Klebsiella pneumoniae.
References
[1] Daniel A. Hussar, Molly A. Walter. “Delafloxacin meglumine, Meropenem trihydrate/vaborbactam, Secnidazole, and Benznidazole.” ACS Applied Bio Materials 58 2 (2018): Pages 223-227.
